The manuscript underwent external, single-blind peer review followed by a focused revision that preserved its original scope and central conclusions. The reviewers’ comments were relevant and proportionate to the nature of a minireview, leading mainly to clarification, evidence calibration, and improvements in organization and readability rather than major restructuring. The revision more clearly distinguishes the relatively consistent dosimetric benefits for the ipsilateral lung and liver from the uncertain effects on the heart, right coronary artery, and contralateral breast, while refining the discussion of RPM, OSMS, ABC, patient selection, breathing training, and per-fraction quality assurance. After acceptance on October 9, 2026, the article was made available online on November 4, 2026. Overall, the editorial and peer-review process was orderly and timely, strengthening the accuracy, balance, and clinical usefulness of the article while preserving the authors’ scientific interpretation.